DNA Ginkgo Bioworks Holdings, Inc. Class A

Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.

$1.23  -0.05 (-3.54%)
As of 03/27/2023 14:11:56 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Materials
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/19/2021
Outstanding shares:  1,570,064,412
Average volume:  23,356,863
Market cap:   $1,931,179,227
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BN6KXF0

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%